D-Mannose for Prevention of Recurrent Urinary Tract Infection Among Women: A Randomized Clinical Trial
Hayward G
Published in JAMA Internal Medicine
Methodology
Double-blind, parallel-group, placebo-controlled randomised clinical trial (MERIT) across 99 UK primary care centres; women aged 18+ with recurrent UTI randomised to 2 g D-mannose powder daily or matched fructose placebo for 6 months.
Key Findings
Among 598 women in UK primary care with recurrent UTI, daily D-mannose (2 g) did not reduce the proportion of women experiencing at least one further medically attended UTI over 6 months (51.0% vs 55.7% with placebo; absolute risk difference -5.7%, 95% CI -13.6% to 2.2%). No differences in symptom duration, antibiotic use, or hospital admission.
Conclusions
Daily D-mannose did not reduce medically attended recurrent UTIs in primary care.
Limitations
Open recruitment from primary care; outcome relied on medically attended episodes rather than microbiologically confirmed UTI; single dose regimen tested; adherence self-reported.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
UK National Institute for Health and Care Research (NIHR) School for Primary Care Research
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.